...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
【24h】

New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.

机译：在慢性丙型肝炎血清样本中，新的多种蛋白质模式区分了肝纤维化阶段和肝细胞癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To identify a multi serum protein pattern as well as single protein markers using surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) for detection and differentiation of liver fibrosis (F1-F2), liver cirrhosis (F4) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV). METHODS: Serum samples of 39 patients with F1/F2 fibrosis, 44 patients with F4 fibrosis, 34 patients with HCC were applied to CM10 arrays and analyzed using the SELDI-TOF ProteinChip System (PBS-IIc; Ciphergen Biosystems) after anion-exchange fractionation. All patients had chronic hepatitis C and histologically confirmed fibrosis stage/HCC. Data were analyzed for protein patterns by multivariate statistical techniques and artificial neural networks. RESULTS: A 4 peptide/protein multimarker panel (7486, 12843, 44293 and 53598 Da) correctly identified HCCs with a sensitivity of 100% and specificity of 85% in a two way-comparison of HCV-cirrhosis versus HCV-HCC training samples (AUROC 0.943). Sensitivity and specificity for identification of HCC were 68% and 80% for random test samples. Cirrhotic patients could be discriminated against patients with F1 or F2 fibrosis using a 5 peptide/protein multimarker pattern (2873, 6646, 7775, 10525 and 67867 Da) with a specificity of 100% and a sensitivity of 85% in training samples (AUROC 0.976) and a sensitivity and specificity of 80% and 67% for random test samples. Combination of the biomarker classifiers with APRI score and alfa-fetopotein (AFP) improved the diagnostic performance. The 6646 Da marker protein for liver fibrosis was identified as apolipoprotein C-I. CONCLUSION: SELDI-TOF-MS technology combined with protein pattern analysis seems a valuable approach for the identification of liver cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C. Most probably a combination of different serum markers will help to identify liver cirrhosis and early-stage hepatocellular carcinomas in the future.
机译：目的：使用表面增强激光解吸/电离飞行时间质谱（SELDI-TOF-MS）来检测和区分肝纤维化（F1-F2），以鉴定多种血清蛋白模式和单个蛋白标记，慢性丙型肝炎病毒（HCV）患者的肝硬化（F4）和肝细胞癌（HCC）。方法：将39例F1 / F2纤维化患者，44例F4纤维化，34例HCC患者的血清样本用于CM10阵列，并在阴离子交换分离后使用SELDI-TOF蛋白芯片系统（PBS-IIc; Ciphergen Biosystems）进行分析。所有患者均患有慢性丙型肝炎，并在组织学上证实为纤维化分期/ HCC。通过多元统计技术和人工神经网络分析数据的蛋白质模式。结果：在HCV肝硬化与HCV-HCC训练样本的两种比较中，一个4肽/蛋白质多标记专家组（7486、12843、44293和53598 Da）正确鉴定了HCC，其敏感性为100％，特异性为85％（ AUROC 0.943）。随机测试样品鉴定HCC的敏感性和特异性分别为68％和80％。肝硬化患者可以使用5种肽/蛋白质多标记模式（2873、6646、7775、10525和67867 Da）区分F1或F2纤维化患者，特异性在训练样本中为100％，灵敏度为85％（AUROC 0.976 ），随机测试样品的敏感性和特异性分别为80％和67％。将生物标志物分类器与APRI评分和α-fetopotein（AFP）结合使用可提高诊断性能。用于肝纤维化的6646 Da标记蛋白被鉴定为载脂蛋白C-1。结论：SELDI-TOF-MS技术与蛋白质模式分析相结合似乎是鉴定慢性丙型肝炎患者肝硬化和肝细胞癌的一种有价值的方法。最有可能的是，不同血清标志物的组合将有助于鉴定肝硬化和早期肝硬化。将来会发生肝癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号